Efficacy News and Research

RSS

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

Nuffield Health Leeds Hospital offers incisionless TOGA Procedure for treatment of obesity

Nuffield Health Leeds Hospital announced today that it will be the first hospital in the UK to offer the incisionless TOGA® Procedure for treatment of obesity commencing in January 2011. The TOGA Procedure has been used to treat over 450 patients worldwide - its incision-free approach is very minimally invasive and offers the benefits of minimal pain and downtime, and an excellent safety profile.

10 Nov 2010

Repros third quarter net loss decreases to $1.2 million

Repros Therapeutics Inc. today announced financial results for the third quarter ended September 30, 2010 and provided an update on corporate actions.

10 Nov 2010

Jefferson awarded $2.6M grant for study on cognitive decline in older African Americans with MCI

Researchers in the Departments of Psychiatry and Neurology at Jefferson Medical College of Thomas Jefferson University were recently awarded a $2.6 million grant from The National Institute of Health to study whether increasing participation in cognitive, physical and/or social activities prevents cognitive decline in older African Americans with Mild Cognitive Impairment (MCI).

10 Nov 2010

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

UCB and U.S. based partner Immunomedics Inc. announced that results from the phase IIB study, EMBLEM, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant reduction in disease activity in adult patients with moderate to severe active SLE.

10 Nov 2010

Regional workshop to discuss diarrheal disease solutions for Asia

Each year, diarrheal disease claims the lives of 1.3 million children under five worldwide and hospitalizes millions more. The vast majority of these deaths occur in developing countries of Asia and Africa, but fortunately, interventions exist that can greatly reduce deaths and save lives. To bring attention to the solutions available today for defeating diarrhea, the Vietnam Ministry of Health, the National Pediatric Hospital of Vietnam, and PATH are hosting a two-day regional workshop where they will present the evidence and lessons learned from initiatives currently underway.

10 Nov 2010

NEWMEDS launches largest database to advance drug development for depressio, schizophrenia

In a remarkable and unprecedented collaboration NEWMEDS (Novel Methods leading to NeW MEdications in Depression and Schizophrenia) have pooled resources to bring together data of 23,401 anonymized patients from 67 trials on 11 compounds in over 25 countries to form the single largest database of clinical trial data ever amassed in psychiatric research.

10 Nov 2010

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the European Medicines Agency (EMA) granted orphan product designation for SBC-102 (Recombinant Human Lysosomal Acid Lipase), the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency.

10 Nov 2010

Immunologix partners with Genscript to develop human antibody therapeutics

Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.

10 Nov 2010

FlexStent Femoropopliteal SE Stent System FIM study results presented at VIVA conference

Final first-in-man (FIM) clinical results on the use of the FlexStent® Femoropopliteal SE Stent System were presented recently at the VIVA conference in Las Vegas by Dr. Andrew Holden of Auckland City Hospital. The clinical results originated from Flexible Stenting Solutions, Inc.'s (FSS) FIM study conducted in New Zealand by Principle Investigator Dr. Andrew Holden, and FSS's supplementary study conducted in Germany by Principle Investigator Dr. Dierk Scheinert of University of Leipzig - Heart Center.

10 Nov 2010

MicroAire and Arthrex enter agreement to settle ECTR patent infringement suit

MicroAire Surgical Instruments LLC and Arthrex Inc. announced today that they have entered an agreement to settle a suit accusing Arthrex of patent infringement and breach of contract. At issue was the patented technology that MicroAire owns for minimally invasive treatment of Carpal Tunnel Syndrome.

10 Nov 2010

Phytomedics awarded $244,000 QTDP grant for development of RA drug

Phytomedics, Inc., a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources, announced today that it has been awarded a grant in the amount of $244,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product PMI-001 for Rheumatoid Arthritis. PMI-001 is presently in Phase 2b/3 development.

9 Nov 2010

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2010 and provided an update on corporate developments.

9 Nov 2010

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.

9 Nov 2010

Discovery Labs reports net operating loss of $6.2 million for third quarter 2010

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first in class therapies for severe respiratory diseases, today provides an update on key pipeline and business initiatives and a financial update for the third quarter ended September 30, 2010.

9 Nov 2010

Angiotech reports $59.0 million total revenue for third quarter 2010

Angiotech Pharmaceuticals, Inc. today announced that it had released its financial results for the third quarter ended September 30, 2010.

9 Nov 2010

Fake antimalarial medications uncovered across Ghana

Substandard and counterfeit versions of thirteen key antimalarial medicines were uncovered in multiple locations across Ghana by the Medicines Quality Monitoring surveillance program. Set up by the Ghana Food and Drugs Board (FDB) in collaboration with the U.S. Pharmacopeial Convention (USP) and the U.S. Agency for International Development (USAID), the program samples antimalarials across the public and private sectors.

9 Nov 2010

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.

9 Nov 2010

Arena third quarter net loss increases to $36.3 million

Arena Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Arena also reported earlier today top-line results from its lorcaserin Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial.

9 Nov 2010

S.A.N.E. Vax calls for federal approval of reliable HPV genotyping test in cervical cancer prevention programs

In a letter addressed to Dr. Harold E. Varmus, director of the NCI, and Dr. Margaret Hamburg, FDA commissioner, Ms. Norma Erickson, president of S.A.N.E. Vax, Inc., requested that these two federal agencies recommend a reliable human papillomavirus (HPV) genotyping test to support the national virology-based cervical cancer prevention program for patient care. Erickson stated: "The NCI knows reliable HPV genotyping is based on using a PCR system with short target sequencing."

9 Nov 2010

Efficacy News and Research

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Nuffield Health Leeds Hospital offers incisionless TOGA Procedure for treatment of obesity

Repros third quarter net loss decreases to $1.2 million

Jefferson awarded $2.6M grant for study on cognitive decline in older African Americans with MCI

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

Regional workshop to discuss diarrheal disease solutions for Asia

NEWMEDS launches largest database to advance drug development for depressio, schizophrenia

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Immunologix partners with Genscript to develop human antibody therapeutics

FlexStent Femoropopliteal SE Stent System FIM study results presented at VIVA conference

MicroAire and Arthrex enter agreement to settle ECTR patent infringement suit

Phytomedics awarded $244,000 QTDP grant for development of RA drug

ARIAD reports $20.4 million net loss for third quarter 2010

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Discovery Labs reports net operating loss of $6.2 million for third quarter 2010

Angiotech reports $59.0 million total revenue for third quarter 2010

Fake antimalarial medications uncovered across Ghana

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena third quarter net loss increases to $36.3 million

S.A.N.E. Vax calls for federal approval of reliable HPV genotyping test in cervical cancer prevention programs

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News